On June 3, Praxis Precision Medicines rose 5.31% in regular trading, trading at $271.78/share, with trading volume of $43.23 million.

The rebound follows a sharp 15.36% intraday decline after the company disclosed that its Power1 study targeting refractory focal onset seizures failed to meet its pre-specified primary efficacy endpoint, a result that posed a significant challenge to the company's core pipeline.

However, the trial achieved its key secondary endpoint of 50% responder rate, with the 30mg dose group demonstrating more significant seizure frequency reduction. Additionally, the core drug Vormatrigine showed favorable tolerability, with discontinuation rates due to adverse events maintained below 10%. After the market digested the initial shock of the primary endpoint miss, these positive secondary data points and the strong safety profile preserved a viable path for continued clinical development, driving the stock to rebound from its lows.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)